According to a recent LinkedIn post from AiM Medical Robotics, the company plans to participate in the LSI USA Emerging Medtech Summit 2026 in Monarch Beach, California, where it will appear in the LSI Alumni Innovator Spotlight. The post highlights progress in MRI‑guided neurosurgical robotics, including a first‑in‑human deep brain stimulation (DBS) procedure at Brigham and Women’s Hospital in Boston.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that Founder & CEO Dr. Gregory Fischer is expected to present AiM’s real‑time MRI‑compatible robotic platform, which is described as delivering submillimeter accuracy for DBS and other intracranial procedures based on more than 15 years and roughly $15 million of NIH‑funded research. This emphasis on technical validation and clinical use may be relevant for investors assessing the maturity and differentiation of the company’s technology.
AiM’s LinkedIn post also suggests that the company will outline its planned path to FDA 510(k) clearance, an initial commercial launch targeting Tier‑1 centers, and a prospective $35 million Series B fundraising round. For investors, this points to a transition from R&D toward regulatory and early commercialization milestones, with corresponding capital requirements that could influence dilution, valuation, and time to revenue.
The post further invites strategic partners in neuromodulation, robotics, and imaging, as well as investors focused on medtech platforms, to engage around clinical and technology partnerships. By emphasizing opportunities in MRI‑guided DBS, epilepsy, and brain tumor applications, the content implies a multi‑indication roadmap that could expand AiM’s addressable market and enhance its competitive position in neurosurgical robotics if execution and regulatory timelines are met.